KOE · 340450.KQ
GC Genome Corporation
₩9,100+₩520 (+6.06%)
GC Genome Corporation’s quoted price sits in the upper half of its reported 52-week range, 13.17% below the high.
Loading market information…
KOE · 205470.KQ · KRW
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
HUMASIS Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 65.35% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
HUMASIS Co., Ltd.’s forward annual dividend is ₩42 per share, paid annual. The forward yield is 1.82% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow HUMASIS Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface proteins, COVID-19 RT-PCR kit, and COVID-19 Variant RT-qPCR kit, as well as MPXV real time PCR kit, a real-time polymerase chain reaction assay for the qualitative detection of nucleic acid from Monkeypox virus. In addition, it offers diagnostic equipment, such as urinalysis, blood glucose meters, and immunodiagnostics tools. Further, it provides other test kits, such as Cotinine to test cotinine in urine; and G6PD, an in vitro diagnostic test that can detect glucose-6-phosphate dehydrogenase in human whole blood. The company was founded in 2000 and is headquartered in Anyang-si, South Korea.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:46 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩9,100+₩520 (+6.06%)
GC Genome Corporation’s quoted price sits in the upper half of its reported 52-week range, 13.17% below the high.
₩14,480+₩80 (+0.56%)
Shinhung Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 12.08% below the high.
₩5,140-₩10 (-0.19%)
Kyongbo Pharmaceutical Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 44.73% below the high.
₩1,203-₩27 (-2.2%)
SAMSUNG PHARM. Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.15% below the high.
₩8,210-₩170 (-2.03%)
HANDOK Inc.’s quoted price sits in the lower half of its reported 52-week range, 32.43% below the high.
₩3,050+₩80 (+2.69%)
MedPacto, Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.74% below the high.
₩6,720-₩60 (-0.88%)
Jeil Pharma Holdings Inc’s quoted price sits in the lower half of its reported 52-week range, 31.78% below the high.
₩1,924+₩4 (+0.21%)
Access Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.11% below the high.
